Immix Biopharma (IMMX) Non-Current Assets (2020 - 2026)

Immix Biopharma has disclosed Non-Current Assets across 7 years of filings, most recently posting $3.5 million for Q1 2026.

• Non-Current Assets for Q1 2026 came in at $3.5 million, up 13.76% year-over-year; the trailing twelve-month figure through Mar 2026 was $13.9 million (up 43.02% YoY), and the FY2025 annual result was $3.6 million, up 31.0% from the prior year.
• Non-Current Assets came in at $3.5 million for Q1 2026 at Immix Biopharma, down from $3.6 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $3.6 million in Q4 2025 to a low of $4126.0 in Q3 2022.
• The 5-year median for Non-Current Assets is $1.4 million (2024), against an average of $1.5 million.
• Across the five-year window, Non-Current Assets soared 3411.05% in 2023 and advanced 13.76% in 2026, its largest moves.
• Immix Biopharma's Non-Current Assets stood at $10284.0 in 2022, then jumped by 1236.15% to $137410.0 in 2023, then jumped by 1901.34% to $2.8 million in 2024, then jumped by 31.0% to $3.6 million in 2025, then slipped by 1.7% to $3.5 million in 2026.
• The last three Non-Current Assets figures came in at $3.5 million (Q1 2026), $3.6 million (Q4 2025), and $3.5 million (Q3 2025), per Business Quant data.